PT3107914T - Compostos de pirazolo[1,5-a]pirimidina-5,7-diamina como inibidores de cdk e utilização terapêutica dos mesmos - Google Patents

Compostos de pirazolo[1,5-a]pirimidina-5,7-diamina como inibidores de cdk e utilização terapêutica dos mesmos

Info

Publication number
PT3107914T
PT3107914T PT15706282T PT15706282T PT3107914T PT 3107914 T PT3107914 T PT 3107914T PT 15706282 T PT15706282 T PT 15706282T PT 15706282 T PT15706282 T PT 15706282T PT 3107914 T PT3107914 T PT 3107914T
Authority
PT
Portugal
Prior art keywords
pyrazolo
pyrimidine
therapeutic use
diamine compounds
cdk inhibitors
Prior art date
Application number
PT15706282T
Other languages
English (en)
Portuguese (pt)
Inventor
Bondke Alexander
kroll Sebastian
Barrett Anthony
Fuchter Matthew
Slafer Brian
Ali Simak
Coombes Charles
Patrick Snyder James
Original Assignee
Univ Emory
Cancer Research Tech Ltd
Ip2Ipo Innovations Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Emory, Cancer Research Tech Ltd, Ip2Ipo Innovations Ltd filed Critical Univ Emory
Publication of PT3107914T publication Critical patent/PT3107914T/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
PT15706282T 2014-02-21 2015-02-20 Compostos de pirazolo[1,5-a]pirimidina-5,7-diamina como inibidores de cdk e utilização terapêutica dos mesmos PT3107914T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB201403093A GB201403093D0 (en) 2014-02-21 2014-02-21 Therapeutic compounds and their use

Publications (1)

Publication Number Publication Date
PT3107914T true PT3107914T (pt) 2019-05-20

Family

ID=50482596

Family Applications (1)

Application Number Title Priority Date Filing Date
PT15706282T PT3107914T (pt) 2014-02-21 2015-02-20 Compostos de pirazolo[1,5-a]pirimidina-5,7-diamina como inibidores de cdk e utilização terapêutica dos mesmos

Country Status (23)

Country Link
US (4) US9932344B2 (enExample)
EP (1) EP3107914B8 (enExample)
JP (1) JP6498212B2 (enExample)
CN (1) CN106103445B (enExample)
AU (1) AU2015220560B2 (enExample)
BR (1) BR112016018633B1 (enExample)
CA (1) CA2939786C (enExample)
CY (1) CY1121588T1 (enExample)
DK (1) DK3107914T3 (enExample)
ES (1) ES2721268T3 (enExample)
GB (1) GB201403093D0 (enExample)
HR (1) HRP20190685T1 (enExample)
HU (1) HUE043122T2 (enExample)
LT (1) LT3107914T (enExample)
ME (1) ME03427B (enExample)
NZ (1) NZ724323A (enExample)
PL (1) PL3107914T3 (enExample)
PT (1) PT3107914T (enExample)
RS (1) RS58704B1 (enExample)
SI (1) SI3107914T1 (enExample)
SM (1) SMT201900266T1 (enExample)
TR (1) TR201905647T4 (enExample)
WO (1) WO2015124941A1 (enExample)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201403093D0 (en) 2014-02-21 2014-04-09 Cancer Rec Tech Ltd Therapeutic compounds and their use
JP6690543B2 (ja) 2014-10-31 2020-04-28 宇部興産株式会社 置換ジヒドロピロロピラゾール化合物
WO2016097004A1 (en) 2014-12-17 2016-06-23 King's College London BICYCLOHETEROARYL-HETEROARYL-BENZOIC ACID COMPOUNDS AS RETINOIC ACID RECEPTOR BETA (RARβ) AGONISTS
AU2016219102B2 (en) * 2015-02-13 2020-10-15 Dana-Farber Cancer Institute, Inc. LRRK2 inhibitors and methods of making and using the same
US10273252B2 (en) 2015-06-15 2019-04-30 Ube Industries, Ltd. Substituted dihydropyrrolopyrazole derivative
WO2017096326A1 (en) 2015-12-02 2017-06-08 Massachusetts Institute Of Technology Method for efficient generation of neurons from non-neuronal cells
JP6832430B2 (ja) 2016-08-31 2021-02-24 アジオス ファーマシューティカルズ, インコーポレイテッド 細胞代謝過程の阻害剤
ES2994013T3 (en) 2017-07-28 2025-01-15 Takeda Pharmaceuticals Co Tyk2 inhibitors and uses thereof
JP7365332B2 (ja) * 2017-08-07 2023-10-19 ジョイント・ストック・カンパニー “バイオキャド” Cdk8/19阻害薬としての新規ヘテロ環式化合物
WO2019035866A1 (en) * 2017-08-15 2019-02-21 The Brigham & Women's Hospital, Inc. COMPOSITIONS AND METHODS FOR TREATING THE TUBEROUS SCLEROSIS COMPLEX
GB201715194D0 (en) * 2017-09-20 2017-11-01 Carrick Therapeutics Ltd Compounds and their therapeutic use
TWI703149B (zh) * 2017-11-16 2020-09-01 美商美國禮來大藥廠 用於抑制cdk7之化合物
MX2020010675A (es) * 2018-04-11 2020-10-28 Qurient Co Ltd Derivados de pirazolo-triazina y/o pirazolo-pirimidina como inhibidor selectivo de cinasa dependiente de ciclina.
WO2019213403A1 (en) 2018-05-02 2019-11-07 Kinnate Biopharma Inc. Inhibitors of cyclin-dependent kinases
CN112638373A (zh) 2018-06-29 2021-04-09 金耐特生物制药公司 细胞周期蛋白依赖性激酶抑制剂
CN112996790B (zh) 2018-10-30 2023-11-03 克洛诺斯生物公司 用于调节cdk9活性的化合物、组合物和方法
US12304913B2 (en) 2018-11-14 2025-05-20 Ube Industries, Ltd. Dihydropyrrolopyrazole derivative
CN109860354B (zh) * 2018-12-28 2020-05-19 南京邮电大学 同质集成红外光子芯片及其制备方法
WO2020186196A1 (en) * 2019-03-13 2020-09-17 The Translational Genomics Research Institute Trisubstituted pyrazolo [1,5-a] pyrimidine compounds as cdk7 inhibitors
EP3997088A4 (en) * 2019-07-10 2022-12-28 Aucentra Therapeutics Pty Ltd Derivatives of 4-(imidazo[l,2-a]pyridin-3-yl)-n-(pyridinyl)pyrimidin- 2-amine as therapeutic agents
IL292519A (en) * 2019-10-29 2022-06-01 Syros Pharmaceuticals Inc Methods for treating cancer in patients identified with a biomarker with cyclin-dependent kinase 7 (cdk7) inhibitors
GB201918541D0 (en) 2019-12-16 2020-01-29 Carrick Therapeutics Ltd Therapeutic compounds and their use
US20230106032A1 (en) * 2020-03-06 2023-04-06 Bayer Aktiengesellschaft Imidazotriazines acting on cancer via inhibition of cdk12
US20230158159A1 (en) * 2020-04-24 2023-05-25 Massachusetts Institute Of Technology Chimeric degraders of cyclin-dependent kinase 9 and uses thereof
AU2022211514B2 (en) * 2021-01-22 2024-06-13 Shanghai Haiyan Pharmaceutical Technology Co., Ltd. Substituted pyrazolo[1,5-a]pyrimidine-7-amine derivative, and compositions and medical use thereof
AU2022271290A1 (en) 2021-05-07 2023-11-23 Kymera Therapeutics, Inc. Cdk2 degraders and uses thereof
GB202108572D0 (en) * 2021-06-16 2021-07-28 Carrick Therapeutics Ltd Therapeutic compounds and their use
WO2023001061A1 (en) * 2021-07-17 2023-01-26 Jingrui Biopharma Co., Ltd. Cdk7 selective inhibitors as anticancer agents
US20250059193A1 (en) * 2021-11-24 2025-02-20 Kronos Bio, Inc. Polymorphic and salt forms of (1s,3s)-n1-(5-(pentan-3-yl)pyrazolo[1,5-a]pyrimidin-7-yl) cyclopentane-1,3-diamine
WO2024102447A1 (en) * 2022-11-10 2024-05-16 Emory University Uses of hydroimidazopyridopyrimidinone derivatives for managing aneurysms or other vascular conditions or diseases
CN120752238A (zh) * 2023-02-20 2025-10-03 江苏正大丰海制药有限公司 作为cdk7激酶抑制剂的杂芳环化合物及其制备和应用
WO2024175024A1 (zh) * 2023-02-21 2024-08-29 杭州德睿智药科技有限公司 作为CDKs抑制剂的新型并杂环类新化合物及其应用
WO2025006569A1 (en) 2023-06-27 2025-01-02 Arvinas Operations, Inc. Combinations of estrogen receptor degraders and cdk7 inhibitors for the treatment of cancer
WO2025057087A1 (en) 2023-09-11 2025-03-20 Assia Chemical Industries Ltd. Solid state forms of samuraciclib
WO2025208104A1 (en) * 2024-03-29 2025-10-02 The Translational Genomics Research Institute Cdk7 inhibitors and methods of use thereof
WO2025208097A1 (en) * 2024-03-29 2025-10-02 The Translational Genomics Research Institute Cdk7 inhibitors and methods of use thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1246823A1 (en) 1999-12-28 2002-10-09 Pharmacopeia, Inc. Pyrimidine and triazine kinase inhibitors
ATE469903T1 (de) 2002-09-04 2010-06-15 Schering Corp Zur behandlung von krebserkrankungen geeignete pyrazolopyrimidine
EP1592689A4 (en) 2003-01-31 2008-12-24 Merck & Co Inc 3-AMINO-4-PHENYLBUTANEAN DERIVATIVES AS DIPEPTIDYLPEPTIDASE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES
JP4564485B2 (ja) 2003-02-28 2010-10-20 帝人ファーマ株式会社 ピラゾロ[1,5−a]ピリミジン誘導体
WO2004087707A1 (en) * 2003-03-31 2004-10-14 Vernalis (Cambridge) Limited Pyrazolopyrimidine compounds and their use in medicine
JO2478B1 (en) 2003-06-19 2009-01-20 جانسين فارماسوتيكا ان. في. (Aminomethyl) -biperidine benzamides as 5 HT4 antagonists
BRPI0616985B1 (pt) * 2005-10-06 2021-10-26 Merck Sharp & Dohme Corp. Composto de pirazolo[1,5-a]pirimidina, e, uso de um composto
CA2688616A1 (en) * 2007-06-05 2008-12-11 Emory University Selective inhibitors for cyclin-dependent kinases
CN102762208A (zh) * 2009-12-04 2012-10-31 赛林药物股份有限公司 作为ck2抑制剂的吡唑嘧啶和相关杂环
WO2012059932A1 (en) 2010-11-01 2012-05-10 Aurigene Discovery Technologies Limited 2, 4 -diaminopyrimidine derivatives as protein kinase inhibitors
EP3409278B8 (en) * 2011-07-21 2020-11-04 Sumitomo Dainippon Pharma Oncology, Inc. Heterocyclic protein kinase inhibitors
EP2634189A1 (en) 2012-03-01 2013-09-04 Lead Discovery Center GmbH Pyrazolo-triazine derivatives as selective cyclin-dependent kinase inhibitors
EP2634190A1 (en) 2012-03-01 2013-09-04 Lead Discovery Center GmbH Pyrazolo-triazine derivatives as selective cyclin-dependent kinase inhinitors
GB201403093D0 (en) 2014-02-21 2014-04-09 Cancer Rec Tech Ltd Therapeutic compounds and their use

Also Published As

Publication number Publication date
EP3107914B1 (en) 2019-01-30
SI3107914T1 (sl) 2019-05-31
CA2939786C (en) 2022-03-08
US20210253583A1 (en) 2021-08-19
US9932344B2 (en) 2018-04-03
PL3107914T3 (pl) 2019-09-30
CN106103445B (zh) 2019-08-09
ME03427B (me) 2020-01-20
JP6498212B2 (ja) 2019-04-10
US10927119B2 (en) 2021-02-23
US20200055862A1 (en) 2020-02-20
HUE043122T2 (hu) 2019-08-28
GB201403093D0 (en) 2014-04-09
US20160362410A1 (en) 2016-12-15
SMT201900266T1 (it) 2019-07-11
ES2721268T3 (es) 2019-07-30
BR112016018633A2 (enExample) 2017-08-08
AU2015220560A1 (en) 2016-10-06
LT3107914T (lt) 2019-05-27
CA2939786A1 (en) 2015-08-27
EP3107914A1 (en) 2016-12-28
NZ724323A (en) 2022-02-25
RS58704B1 (sr) 2019-06-28
BR112016018633B1 (pt) 2022-08-30
CN106103445A (zh) 2016-11-09
US10414772B2 (en) 2019-09-17
HRP20190685T1 (hr) 2019-06-14
AU2015220560B2 (en) 2019-05-16
JP2017506250A (ja) 2017-03-02
DK3107914T3 (en) 2019-04-29
US11566029B2 (en) 2023-01-31
WO2015124941A1 (en) 2015-08-27
TR201905647T4 (tr) 2019-05-21
EP3107914B8 (en) 2019-07-17
US20180273540A1 (en) 2018-09-27
CY1121588T1 (el) 2020-05-29

Similar Documents

Publication Publication Date Title
PL3107914T3 (pl) Związki pirazolo[1,5-a]pirymidyno-5,7-diaminowe jako inhibitory CDK i ich zastosowanie terapeutyczne
IL260923B (en) History of pyrazolo[5,1-a]pyrazin-4-yl as jak inhibitors
IL254224A0 (en) 7-substituted 5-alkyl-[4,2,1]triazolo[5,1-a]pyrimidine derivatives as pde2 inhibitors
HK1245247A1 (zh) 溴结构域的抑制剂
IL266305B (en) History of [4,2,1]triazolo[5,1-a]pyrimidine as pde2 inhibitors
ZA201802842B (en) [1,2,4]triazolo[1,5-a]pyrimidin-7-yl compound
IL247947B (en) 7,6,5,4-tetrahydro-pyrazolo[5,1-a]pyrazine compounds and 8,7,6,5-tetrahydro-h4-pyrazolo[5,1-a][4,1]diazepine compounds as ros1 inhibitors
ZA201800485B (en) Pyrazolo[1,5-a]triazin-4-amine derivatives useful in therapy
ZA201605666B (en) Pyrazolo[1,5-a]pyrimidines as antiviral compounds
IL290419B (en) Imidazo[a-1,5]pyrazine derivatives as inhibitors of pi3k delta
ZA201701207B (en) [1,2,4]triazolo[4,3-b]pyridazines for use in the treatment of proliferative diseases
IL258070A (en) Cyclic ether history of pyrazolo[5,1-a]pyrimidine-3-carboxamide
IL253427B (en) The result of pyrazolo[3,4-d]pyrimidine and its use in the treatment of Jericho rose